{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:26Z","timestamp":1782417506484,"version":"3.54.5"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Enzyme replacement therapy (ERT) with alglucosidase alfa markedly improves outcomes in infantile-onset Pompe disease, yet hypersensitivity reactions may interrupt treatment and require desensitization. We report a very young infant in whom ERT was successfully maintained after allergic reactions through a structured desensitization protocol.<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n A 3-month-old male with infantile-onset Pompe disease developed generalized urticaria during the seventh alglucosidase alfa infusion despite premedication and infusion rate adjustment. Skin testing was not feasible due to age. After obtaining informed consent, desensitization was initiated in a specialized setting. Initial three- and four-bag protocols were unsuccessful because of recurrent urticaria. A final five-bag, sixteen-dose protocol using enzyme concentrations from 0.0005 to 1\u202fmg\/mL enabled the full therapeutic dose to be administered safely. The same regimen was subsequently applied in following infusions without recurrence of symptoms.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This case demonstrates that desensitization can be effectively implemented even in very young infants with Pompe disease who experience hypersensitivity during ERT. A carefully designed protocol and close clinical monitoring allow continuation of this life-saving therapy when no alternative treatment exists.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2025-0599","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:56:22Z","timestamp":1768798582000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful desensitization to alglucosidase alfa in a very young infant with Pompe disease"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-8055","authenticated-orcid":false,"given":"Funda","family":"Aytekin G\u00fcvenir","sequence":"first","affiliation":[{"name":"Department of Pediatric Allergy\/Immunology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-7192","authenticated-orcid":false,"given":"G\u00f6khan","family":"Y\u00f6r\u00fcs\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy\/Immunology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7648-0352","authenticated-orcid":false,"given":"Zeynep","family":"\u015eeng\u00fcl Emeksiz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy\/Immunology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"},{"name":"Department of Pediatric Allergy\/Immunology , University of Health Sciences, Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1713","authenticated-orcid":false,"given":"Oya","family":"K\u0131reker K\u00f6yl\u00fc","sequence":"additional","affiliation":[{"name":"Department of Pediatric Metabolism , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-300X","authenticated-orcid":false,"given":"Aynur","family":"K\u00fc\u00e7\u00fck\u00e7ongar Yava\u015f","sequence":"additional","affiliation":[{"name":"Department of Pediatric Metabolism , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3241-2005","authenticated-orcid":false,"given":"Emine","family":"Dibek M\u0131s\u0131rl\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy\/Immunology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"},{"name":"Department of Pediatric Allergy\/Immunology , University of Health Sciences, Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026011904561540300_j_jpem-2025-0599_ref_001","doi-asserted-by":"crossref","unstructured":"Taverna, S, Cammarata, G, Colomba, P, Sciarrino, S, Zizzo, C, Francofonte, D, et al.. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY) 2020;12:15856\u201374. https:\/\/doi.org\/10.18632\/aging.103794.","DOI":"10.18632\/aging.103794"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_002","doi-asserted-by":"crossref","unstructured":"Colella, P. Advances in Pompe disease treatment: from enzyme replacement to gene therapy. Mol Diagn Ther 2024;28:703\u201319. https:\/\/doi.org\/10.1007\/s40291-024-00733-x.","DOI":"10.1007\/s40291-024-00733-x"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_003","doi-asserted-by":"crossref","unstructured":"Parini, R, De Lorenzo, P, Dardis, A, Burlina, A, Cassio, A, Cavarzere, P, et al.. Long-term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet J Rare Dis 2018;13:32. https:\/\/doi.org\/10.1186\/s13023-018-0771-0.","DOI":"10.1186\/s13023-018-0771-0"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_004","doi-asserted-by":"crossref","unstructured":"El-Gharbawy, AH, Mackey, J, DeArmey, S, Westby, G, Grinnell, SG, Malovrh, P, et al.. An individually modified approach to desensitize infants and young children with Pompe disease and significant reactions to alglucosidase alfa infusions. Mol Genet Metabol 2011;104:118\u201322. https:\/\/doi.org\/10.1016\/j.ymgme.2011.07.004.","DOI":"10.1016\/j.ymgme.2011.07.004"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_005","doi-asserted-by":"crossref","unstructured":"Toh, TSW, Chong, KW, Goh, AEN, Goh, JCY, Ting, TW, Tan, ES, et al.. Enzyme replacement therapy desensitization in a child with infantile-onset Pompe disease. Asian Pac J Allergy Immunol 2022;40:414\u20137. https:\/\/doi.org\/10.12932\/AP-060919-0638.","DOI":"10.12932\/AP-060919-0638"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_006","doi-asserted-by":"crossref","unstructured":"Yang, BC, Castells, MC. The who, what, where, when, why, and how of drug desensitization. Immunol Allergy Clin 2022;42:403\u201320. https:\/\/doi.org\/10.1016\/j.iac.2021.12.004.","DOI":"10.1016\/j.iac.2021.12.004"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_007","doi-asserted-by":"crossref","unstructured":"Brown, SG. Clinical features and severity grading of anaphylaxis. J\u00a0Allergy Clin Immunol 2004;114:371\u20136. https:\/\/doi.org\/10.1016\/j.jaci.2004.04.029.","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_008","doi-asserted-by":"crossref","unstructured":"Lessard, LER, Tard, C, Salort-Campana, E, Sacconi, S, B\u00e9hin, A, Bassez, G, et al.. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in late-onset Pompe disease: experience from the French Pompe Registry. Mol Genet Metabol 2023;139:107611. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107611.","DOI":"10.1016\/j.ymgme.2023.107611"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_009","doi-asserted-by":"crossref","unstructured":"Yagmur, IT, Unal Uzun, O, Kucukcongar Yavas, A, Kulhas Celik, I, Toyran, M, Gunduz, M, et al.. Management of hypersensitivity reactions to enzyme replacement therapy in children with lysosomal storage diseases. Ann Allergy Asthma Immunol 2020;125:460\u20137. https:\/\/doi.org\/10.1016\/j.anai.2020.07.010.","DOI":"10.1016\/j.anai.2020.07.010"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_010","doi-asserted-by":"crossref","unstructured":"Lipinski, SE, Lipinski, MJ, Burnette, A, Platts-Mills, TA, Wilson, WG. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metabol 2009;98:319\u201321. https:\/\/doi.org\/10.1016\/j.ymgme.2009.07.001.","DOI":"10.1016\/j.ymgme.2009.07.001"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_011","doi-asserted-by":"crossref","unstructured":"Baruteau, J, Broomfield, A, Crook, V, Finnegan, N, Harvey, K, Burke, D, et al.. Successful desensitisation in a patient with CRIM-positive infantile-onset Pompe disease. JIMD Rep 2014;12:99\u2013102. https:\/\/doi.org\/10.1007\/8904_2013_250.","DOI":"10.1007\/8904_2013_250"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_012","doi-asserted-by":"crossref","unstructured":"Spataro, F, Solimando, AG, Desantis, V, Vacca, A, Di Girolamo, A, Ria, R, et al.. How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? Orphanet J Rare Dis 2025;20:287. https:\/\/doi.org\/10.1186\/s13023-025-03844-8.","DOI":"10.1186\/s13023-025-03844-8"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_013","doi-asserted-by":"crossref","unstructured":"Cernadas, JR, Brockow, K, Romano, A, Aberer, W, Torres, MJ, Bircher, A, et al.. General considerations on rapid desensitization for drug hypersensitivity: a consensus statement. Allergy 2010;65:1357\u201366. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02441.x.","DOI":"10.1111\/j.1398-9995.2010.02441.x"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_014","doi-asserted-by":"crossref","unstructured":"Ertoy Karagol, HI, Inci, A, Terece, SP, Kilic, A, Demir, F, Yapar, D, et al.. Long-term experience with anaphylaxis and desensitization to alglucosidase alfa in Pompe disease. Int Arch Allergy Immunol 2023;184:370\u20135. https:\/\/doi.org\/10.1159\/000528343.","DOI":"10.1159\/000528343"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_015","doi-asserted-by":"crossref","unstructured":"Karagol, IH, Bakirtas, A, Yilmaz, O, Topal, E, Kucukcongar, A, Ezgu, FS, et al.. Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa. Allergol Immunopathol 2014;42:372\u20135. https:\/\/doi.org\/10.1016\/j.aller.2013.02.012.","DOI":"10.1016\/j.aller.2013.02.012"},{"key":"2026011904561540300_j_jpem-2025-0599_ref_016","doi-asserted-by":"crossref","unstructured":"Capanoglu, M, Dibek Misirlioglu, E, Azkur, D, Vezir, E, Guvenir, H, Gunduz, M, et al.. IgE-mediated hypersensitivity and desensitisation with recombinant enzymes in Pompe disease and type I and type VI mucopolysaccharidosis. Int Arch Allergy Immunol 2016;169:198\u2013202. https:\/\/doi.org\/10.1159\/000446154.","DOI":"10.1159\/000446154"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0599\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:56:24Z","timestamp":1768798584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0599\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":16,"alternative-id":["10.1515\/jpem-2025-0599"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0599","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}